Modulation of gamma-secretase reduces beta-amyloid deposition in a transgenic mouse model of Alzheimer's disease.
Alzheimer's disease (AD) is characterized pathologically by the abundance of senile plaques and neurofibrillary tangles in the brain. We synthesized over 1200 novel gamma-secretase modulator (GSM) compounds that reduced Abeta(42) levels without inhibiting epsilon-site cleavage of APP and Notch, the generation of the APP and Notch intracellular domains, respectively. These compounds also reduced Abeta(40) levels while concomitantly elevating levels of Abeta(38) and Abeta(37). Immobilization of a potent GSM onto an agarose matrix quantitatively recovered Pen-2 and to a lesser degree PS-1 NTFs from cellular extracts. Moreover, oral administration (once daily) of another potent GSM to Tg 2576 transgenic AD mice displayed dose-responsive lowering of plasma and brain Abeta(42); chronic daily administration led to significant reductions in both diffuse and neuritic plaques. These effects were observed in the absence of Notch-related changes (e.g., intestinal proliferation of goblet cells), which are commonly associated with repeated exposure to functional gamma-secretase inhibitors (GSIs).
Kounnas
Maria Z
MZ
TorreyPines Therapeutics, Inc., La Jolla, CA 92037, USA.
Danks
Anne M
AM
Cheng
Soan
S
Tyree
Curtis
C
Ackerman
Elizabeth
E
Zhang
Xulun
X
Ahn
Kwangwook
K
Nguyen
Phuong
P
Comer
Dan
D
Mao
Long
L
Yu
Chengzhi
C
Pleynet
David
D
Digregorio
Paul J
PJ
Velicelebi
Gonul
G
Stauderman
Kenneth A
KA
Comer
William T
WT
Mobley
William C
WC
Li
Yue-Ming
YM
Sisodia
Sangram S
SS
Tanzi
Rudolph E
RE
Wagner
Steven L
SL
D000544:Alzheimer Disease / Q000235:genetics* / Q000378:metabolism*; D053829:Amyloid Precursor Protein Secretases / Q000378:metabolism*; D016229:Amyloid beta-Peptides / Q000276:immunology / Q000378:metabolism*; D016564:Amyloid beta-Protein Precursor / Q000235:genetics; D000704:Analysis of Variance; D000818:Animals; D000906:Antibodies / Q000494:pharmacology; D002087:Butyrates / Q000494:pharmacology; D015820:Cadherins / Q000378:metabolism; D002478:Cells, Cultured; D006224:Cricetinae; D003412:Cricetulus; D004195:Disease Models, Animal; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000737:chemistry / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay / Q000379:methods; D005260:Female; D031541:Fluorescence Resonance Energy Transfer / Q000379:methods; D005786:Gene Expression Regulation / Q000187:drug effects; D006801:Humans; D006846:Hydrocarbons, Halogenated / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D010446:Peptide Fragments / Q000378:metabolism; D053764:Presenilin-1 / Q000235:genetics; D051381:Rats; D051880:Receptors, Notch / Q000378:metabolism; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization / Q000379:methods; D014162:Transfection / Q000379:methods
C497115:4-(2-((1R)-1-(((4-chlorophenyl)sulfonyl)-2,5-difluoroanilino)ethyl)-5-fluorophenyl)butanoic acid; D016229:Amyloid beta-Peptides; D016564:Amyloid beta-Protein Precursor; D000906:Antibodies; D002087:Butyrates; D015820:Cadherins; D004791:Enzyme Inhibitors; D006846:Hydrocarbons, Halogenated; C508853:PSEN1 protein, human; D010446:Peptide Fragments; D053764:Presenilin-1; D051880:Receptors, Notch; C078592:amyloid beta-protein (1-40); C075222:amyloid beta-protein (1-42); D053829:Amyloid Precursor Protein Secretases
Physiology (Bethesda). 2008 Aug;23:194-204
18697993
J Clin Invest. 1999 Nov;104(10):1329-32
10562291
J Pharmacol Exp Ther. 2007 Feb;320(2):552-8
17099072
J Virol. 2010 Apr;84(7):3408-12
20032192
J Med Chem. 2009 Oct 22;52(20):6169-88
19694467
Cell. 2005 Feb 25;120(4):545-55
15734686
Expert Rev Neurother. 2009 May;9(5):661-79
19402777
Nat Rev Neurosci. 2002 Apr;3(4):281-90
11967558
Toxicol Sci. 2004 Nov;82(1):341-58
15319485
Curr Opin Drug Discov Devel. 2007 Jul;10(4):392-402
17659480
Neurology. 2006 Feb 28;66(4):602-4
16505324
J Biol Chem. 2004 Mar 26;279(13):12876-82
14709552
J Biol Chem. 2003 Nov 14;278(46):46107-16
12949072
Nature. 2001 Nov 8;414(6860):212-6
11700559
Biochemistry. 2004 Jan 20;43(2):323-33
14717586
Genes Dev. 2000 Nov 15;14(22):2799-806
11090127
Science. 2001 Jul 6;293(5527):115-20
11441186
J Biol Chem. 2005 Jan 21;280(3):1992-2001
15537629
J Pharmacol Exp Ther. 2009 Nov;331(2):598-608
19671883
Proc Natl Acad Sci U S A. 2009 Dec 1;106(48):20228-33
19906985
Nature. 1999 Apr 8;398(6727):518-22
10206645
Nature. 2000 Jun 8;405(6787):689-94
10864326
EMBO J. 2002 Apr 15;21(8):1948-56
11953314
J Neurochem. 2001 Jan;76(1):173-81
11145990
Science. 1996 Oct 4;274(5284):99-102
8810256
J Biol Chem. 2003 Sep 5;278(36):34427-37
12826675
J Pharmacol Exp Ther. 2007 Dec;323(3):822-30
17895400
J Neurosci. 2003 Oct 1;23(26):8844-53
14523085
Science. 2009 May 1;324(5927):639-42
19299585
J Biol Chem. 2002 Aug 30;277(35):31499-505
12072428
J Pharmacol Exp Ther. 2006 Dec;319(3):1133-43
16946102
J Biol Chem. 2008 Jan 11;283(2):677-83
17962197
J Neurosci. 2009 Oct 14;29(41):12787-94
19828790
Biochem Pharmacol. 2005 Feb 15;69(4):689-98
15670587
Nature. 2008 Jun 12;453(7197):925-9
18548070
Mol Cell. 2000 Feb;5(2):197-206
10882062
Nat Rev Mol Cell Biol. 2004 Jun;5(6):499-504
15173829